Table 3.
Inhaler prescriptions by spirometry result
| Spirometry and COPD stages | SAMA/SABA | LAMA/LABA | +ICS | P value |
| Restrictive impairment (n=89) | 11/28 (39%) | 9/24 (38%) | 69/220 (31%) | 0.577 |
| +BDR (n=9) | 0/25 (0%) | 2/22 (9%) | 7/180 (4%) | 0.202 |
| Airway obstruction (n=183) | 14/29 (48%) | 17/27 (63%) | 152/227 (67%) | 0.138 |
| +BDR (n=46) | 4/25 (16%) | 5/22 (23%) | 37/180 (21%) | 0.871 |
| Mixed impairment (n=165) | 12/28 (43%) | 13/24 (54%) | 140/220 (64%) | 0.077 |
| +BDR (n=46) | 4/25 (16%) | 5/22 (23%) | 37/180 (21%) | 0.871 |
| BDR (total) (n=55) | 4/25 (16%) | 7/22 (32%) | 44/180 (24%) | 0.440 |
| Any impairment (n=275) | 25/29 (86%) | 27/27 (100%) | 223/227 (98%) | 0.014* |
| GOLD | ||||
| GOLD I (n=2) | 0/13 (0%) | 1/15 (7%) | 1/146 (1%) | 0.085 |
| GOLD II (n=25) | 3/13 (23%) | 5/15 (33%) | 17/146 (12%) | |
| GOLD III (n=92) | 7/13 (54%) | 5/15 (33%) | 80/146 (55%) | |
| GOLD IV (n=55) | 3/13 (23%) | 4/15 (27%) | 48/146 (33%) | |
| COPD-X | ||||
| NA (FEV1>80%) (n=11) | 1/14 (7%) | 3/17 (18%) | 7/152 (5%) | 0.114 |
| Mild (n=12) | 1/14 (7%) | 3/17 (18%) | 8/152 (5%) | |
| Moderate (n=57) | 5/14 (36%) | 4/17 (24%) | 48/152 (32%) | |
| Severe (n=103) | 7/14 (50%) | 7/17 (41%) | 89/152 (59%) |
GOLD stages.
0—FEV1/FVC post-BD ≥0.7.
I—FEV1/FVC post-BD <0.7 and FEV1 post-BD (% predicted) ≥80%.
II—FEV1/FVC post-BD <0.7 and FEV1 post-BD (% predicted) ≥50% and <80%.
III—FEV1/FVC post-BD <0.7 and FEV1 post-BD (% predicted) ≥30% and <50%.
IV—FEV1/FVC post-BD <0.7 and FEV1 post-BD (% predicted) <30%.
Denominators in the above table show the number of SAMA/SABA, LAMA/LABA or +ICS patients with information available to categorise into each spirometry impairment category.
P value obtained via χ2 or Fisher’s exact test (cases where cells values were <10).
*p<0.05.
†In the absence of post- BD values, pre-BD values were used.
BD, bronchodilator; BDR, BD response; COPD-X, Australian concise tool for chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; ICS, inhaled corticosteroids; LABA, long-acting β-agonists; LAMA, long-acting muscarinic antagonists; NA, not available; SABA, short-acting bronchodilator; SAMA, short-acting muscarinic antagonists.